138
Participants
Start Date
June 30, 2007
Primary Completion Date
January 31, 2010
Study Completion Date
April 30, 2012
Placebo
Inactive dummy of AMG 655.
AMG 479
AMG 479 is fully human monoclonal antagonist antibody targeted against insulin-like growth factor receptor type 1 (IGF-1R).
AMG 655
AMG 655 is a fully human monoclonal agonist antibody directed against TRAIL Receptor 2 (TR-2).
Research Site, New York
Research Site, Albany
Research Site, Pittsburgh
Research Site, Philadelphia
Research Site, Westminster
Research Site, Baltimore
Research Site, Durham
Research Site, Hickory
Research Site, Greenville
Research Site, Marietta
Research Site, Atlanta
Research Site, Atlanta
Research Site, Orlando
Research Site, Miami
Research Site, Columbus
Research Site, Harvey
Research Site, Chicago
Research Site, St Louis
Research Site, Dallas
Research Site, Tyler
Research Site, Round Rock
Research Site, Austin
Research Site, Austin
Research Site, Austin
Research Site, Henderson
Research Site, Los Angeles
Research Site, Redondo Beach
Research Site, Santa Monica
Research Site, Long Beach
Research Site, Northridge
Research Site, Alhambra
Research Site, La Jolla
Research Site, Rancho Mirage
Research Site, Fullerton
Research Site, Oxnard
Research Site, Bakersfield
Research Site, Santa Maria
Research Site, San Francisco
Research Site, Eugene
Research Site, Tacoma
Research Site, Yakima
Research Site, Boston
Research Site, Boston
Research Site, Providence
Lead Sponsor
NantCell, Inc.
INDUSTRY